Abstracts tagged "autoantigens"

Abstract Number: 2658 • 2017 ACR/ARHP Annual Meeting
4-Hydroxy-2-Nonenal Serum Protein-Adducts and Anti-4-Hydroxy-2-Nonenal-Protein Adduct Antibodies in SLE
Biji T Kurien^1,2,3 and R. Hal Scofield⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, ³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, complex disease and autoantibodies to self-antigens are a characteristic feature of the disorder. Our group and others…
Abstract Number: 26 • 2017 ACR/ARHP Annual Meeting
Single B Cell Analysis Revealed the Relationship Among the Cytokine Profile, Antibody Affinity, and Pathogenic Roles of Autoantigen-Reactive B Cells in Systemic Sclerosis
Takemichi Fukasawa¹, Ayumi Yoshizaki², Satoshi Ebata¹, Kouki Nakamura¹, Ryosuke Saigusa¹, Takashi Yamashita¹, Yoshihide Asano³, Yutaka Kazoe⁴, Kazuma Mawatari⁴, Takehiko Kitamori⁴ and Shinichi Sato⁵, ¹Dermatology, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ²Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Applied Chemistry, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ⁴Applied Chemistry, University of Tokyo, Graduate School of Engineering, Tokyo, Japan, ⁵Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan
Background/Purpose: Recent studies have indicated that B cells play critical roles in systemic autoimmunity and disease expression through various functions such as induction of the…
Abstract Number: 39 • 2017 ACR/ARHP Annual Meeting
Protein Array Technology Identifies Rituximab-Treated Non-Responder Rheumatoid Arthritis Patients to Generate New Autoantibody Repertoires during Treatment
Zoltán Konthur¹, Melvin Michael Wiemkes², Thomas Häupl², Gerd R. Burmester² and Karl Skriner², ¹Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany, ²Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany
Background/Purpose: Rituximab (RTX) has shown clinical efficacy but up to 40 % of RTX treated rheumatoid arthritis (RA) patients are poor responders (Ann-Rheum-Dis. 2005 Feb;64(2):246-52)…
Abstract Number: 17 • 2017 Pediatric Rheumatology Symposium
Anti-endothelial cell antibodies in juvenile dermatomyositis
Rie Karasawa¹, Mayumi Tamaki¹, Toshiko Sato¹, Megumi Tanaka¹, Kazuo Yudoh² and James Jarvis³, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan, ³Pediatrics, SUNY Buffalo School of Medicine, Buffalo, NY
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common form of inflammatory myopathy in children. Although classified as a myopathy, involved tissues in JDM are characterized…
Abstract Number: 178 • 2016 ACR/ARHP Annual Meeting
Alpha-Enolase Promotes Pro-Inflammatory Phenotype of Monocytes-Derived Macrophages
Pascal Rottenberg^1,2, Manuel Fréret^1,2, Sébastien Calbo¹ and Olivier Vittecoq^1,2, ¹INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, ²Rheumatology, Rouen University Hospital, Rouen, France
Background/Purpose: Monocytes of healthy donors were cultured with M-CSF (gcultured with ENO1, or control BSA, to investigate its effect on monocytes differentiation and macrophages polarization.…
Abstract Number: 813 • 2016 ACR/ARHP Annual Meeting
Identifying and Assessing Subgroups in Systemic Sclerosis Patients Based on Comprehensive Autoantibody Profiling
Petra Budde¹, Hans-Dieter Zucht¹, Heike Göhler¹, Klaus Marquart¹, Peter Schulz-Knappe¹, Matthias Schneider² and Nicolas Hunzelmann³, ¹Protagen AG, Dortmund, Germany, ²Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ³Department of Dermatology, University of Cologne, Cologne, Germany
Background/Purpose: Systemic sclerosis (SSc) is a remarkably heterogeneous autoimmune disease, for which effective disease-modifying therapies are still lacking. The most widely used classification divides SSc…
Abstract Number: 815 • 2016 ACR/ARHP Annual Meeting
The Novel Anti-BICD2 Autoantibody Potentially Predicts a Favorable Disease Course in SSc
Johannes Schulte-Pelkum¹, Daniel Wirtz¹, Petra Budde¹, Hans-Dieter Zucht¹, Peter Schulz-Knappe¹, Prof. Dr. Matthias Schneider², Suzana Jordan³, Oliver Distler³, Britta Maurer³ and Nicolas Hunzelmann⁴, ¹Protagen AG, Dortmund, Germany, ²Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany, ³Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Dermatology, University of Cologne, Cologne, Germany
Background/Purpose: To evaluate clinical associations of our recently discovered systemic sclerosis-specific auto-antigen BICD2 in clinically well characterized systemic sclerosis (SSc) cohorts from two tertiary referral…
Abstract Number: 915 • 2016 ACR/ARHP Annual Meeting
Establishment of a Powerful Method to Identify Autoantigens Expressed on the Cell Surface
Tsuyoshi Shirai¹, Hiroshi Fujii¹, Tomoyuki Muto², Yuko Shirota¹, Yoko Fujita³, Tomonori Ishii¹ and Hideo Harigae¹, ¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ²Tohoku University Graduate School of Medicine, Sendai, Japan, ³Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan
Background/Purpose: Autoantibodies which recognize integral membrane proteins are generally accepted as pathogenic. However, it had been technically difficult to identify plasma membrane proteins as autoantigens…
Abstract Number: 990 • 2016 ACR/ARHP Annual Meeting
Autoimmunity to Multiple Antigens Is Expanded in at-Risk Family Members Beyond the Disease Specific Patterns of the SLE or RA Proband
Judith A. James¹, Krista M. Bean², Hua Chen², Kendra A. Young³, Elizabeth A. Bemis⁴, Jennifer Seifert⁵, Maria Sargent⁶, Kevin D. Deane⁷, Bill Robinson⁸, David A. Hafler⁹, Kevin O'Conner¹⁰, Jane H. Buckner¹¹, Joel M. Guthridge¹², Jill M. Norris¹³ and V. Michael Holers¹⁴, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Epidemiology, University of Colorado Denver, Aurora, CO, ⁴Epidemiology, Colorado School of Public Health, Aurora, CO, ⁵University of Colorado, Denver, CO, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁸Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁹Neurology and Immunobiology, Yale School of Medicine, New Haven, CT, ¹⁰Yale University, New Haven, CT, ¹¹Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³University of Colorado Denver, Aurora, CO, ¹⁴Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Certain autoantibodies (aabs) are highly disease specific, can be detected prior to the onset of clinically apparent disease and oftentimes increase in number and…
Abstract Number: 1083 • 2016 ACR/ARHP Annual Meeting
Discovery and Subsequent Diagnostic Verification of Autoantibodies Against the Major Vault Protein (MVP) in Systemic Lupus Erythematosus
Petra Budde¹, Johannes Schulte-Pelkum¹, Daniel Wirtz¹, Hans-Dieter Zucht¹, Heike Göhler¹, Stefan Vordenbäumen², Peter Schulz-Knappe¹ and Matthias Schneider³, ¹Protagen AG, Dortmund, Germany, ²Rheumatology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, ³Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: In systemic lupus erythematosus (SLE), early diagnosis and prognostic stratification are still great challenges. The broad characterization of the autoantibody repertoire in SLE is…
Abstract Number: 1208 • 2016 ACR/ARHP Annual Meeting
High-Throughput Screening Discovers Multiple Novel Autoantibodies in Rheumatoid Arthritis, Systemic Lupus, Systemic Sclerosis and Sjogrens Syndrome
Peter Schulz-Knappe¹, Hans-Dieter Zucht¹, Petra Budde¹, Heike Göhler¹, Daniel Wirtz¹, Johannes Schulte-Pelkum¹, Stefan Vordenbäumen², Torsten Witte³ and Prof. Dr. Matthias Schneider⁴, ¹Protagen AG, Dortmund, Germany, ²Rheumatology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, ³Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ⁴Department of Rheumatology & Hiller Research Unit, Heinrich-Heine University, Düsseldorf, Germany
Background/Purpose: Diagnostic biomarkers are decision-making tools in clinical lab routine and are of growing importance for clinical management of patients. In autoimmune diseases, one important…
Abstract Number: 1834 • 2016 ACR/ARHP Annual Meeting
Commensal Ro60 Autoantigen Ortholog Cross-Reactivity in Human Lupus and Gnotobiotic Models
Teri Greiling¹, Carina Dehner², Stephen Renfroe³, Xinguo Chen⁴, Kevin Hughes⁴, Silvio M. Vieira³, William Ruff³, Marco Boccitto⁴, Andrew Goodman⁵, Sandra L. Wolin⁴ and Martin Kriegel^3,6, ¹Dermatology and Immunobiology, Yale School of Medicine, New Haven, CT, ²Immunobiology, Yale School of Medicine, new haven, CT, ³Immunobiology, Yale School of Medicine, New Haven, CT, ⁴Cell Biology, Yale School of Medicine, New Haven, CT, ⁵Microbial Pathogenesis, Yale School of Medicine, New Haven, CT, ⁶Medicine/Division of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: The earliest autoantibodies in lupus are directed against the autoantigen Ro60, an RNA binding protein with orthologs that we identified in a subset of…
Abstract Number: 2112 • 2016 ACR/ARHP Annual Meeting
Disease-Activity Associated Autoantibodies to Malondialdehyde-Modified Proteins Can be Isolated from Synovial B Cells in RA
Caroline Grönwall¹, Khaled Amara¹, Uta Hardt¹, Lelise Getu², Jeffrey D. Greenberg³, Robert M Clancy³, Vivianne Malmström⁴ and Gregg J. Silverman³, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Malondialdehyde (MDA) is a naturally occurring reactive aldehyde that arises during apoptosis or as a consequence of elevated reactive oxygen species and lipid peroxidation.…
Abstract Number: 3020 • 2016 ACR/ARHP Annual Meeting
Citrullination of Inhibitor of DNA Binding-1 at Specific Locations Leads to Autoantigenicity in Rheumatoid Arthritis
Ray A. Ohara¹, Henriette A. Remmer², Phillip L. Campbell³, David A. Fox³ and Jeffrey H. Ruth³, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI
Background/Purpose: Inhibitor of DNA binding-1 (Id1) is a nuclear transcription factor that regulates cell growth and differentiation via selective binding and sequestering of other transcription…
Abstract Number: 1851 • 2015 ACR/ARHP Annual Meeting
Antibody Against Ribonuclease-H Is a Novel Autoantibody Specifically Recognized in Systemic Lupus Erhythematosus
Kazuhisa Nozawa¹, Kentaro Doe², Kaori Hiruma³, Yusuke Yamada⁴ and Yoshinari Takasaki⁵, ¹2-1-1 Hongo Bunkyo-ku, Juntendo University, Tokyo, Japan, ²2-1-1 Hongo, Bunkyo-Ku, Juntendo University School of Medicine, Tokyo, Japan, ³Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁵Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Proliferating cell nuclear antigen (PCNA) is known to be an autoantigen specifically recognized in patients with SLE. PCNA constitutes PCNA-complex along with several PCNA-binding…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.